Research library

A

grade

Mazdutide showed dose-dependent reductions in body weight and HbA1c in adults with obesity and type 2 diabetes, but the evidence is limited and requires further validation.

MD -11.1% body weight vs placebo at 6 mg, n=2292.

summary

A

grade

This meta-analysis indicates that obesity drugs can lead to significant weight loss, but often at the cost of increased adverse events, and many do not meaningfully improve quality of life.

Mean difference in weight loss with tirzepatide -14.9%, 95% CI -16.0% to -13.9%, n=99,791.

summary

A

grade

Exenatide and glucagon co-infusion may increase myocardial glucose uptake and improve certain markers of heart function in adults with type 2 diabetes, but further research is needed to confirm these effects and their clinical significance.

Myocardial glucose uptake increased from a median of 9.2×10^-3 µmol/g/min to 20×10^-3 µmol/g/min, n=8, P<0.05.

summary

B

grade

GLP-1 receptor agonists like semaglutide have shown a 16% mean weight reduction in adolescents over 68 weeks, but caution is advised regarding long-term safety and efficacy.

16% mean body weight reduction over 68 weeks with semaglutide.

summary

C

grade

Mazdutide showed promise in improving metabolic dysfunction and inflammation in a mouse model of MASLD, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary